|Table of Contents|

Relationship between serum apolipoprotein and cognitive decline after different whole-brain radiotherapy techniques for breast cancer with brain metastases

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 19
Page:
3688-3693
Research Field:
Publishing date:

Info

Title:
Relationship between serum apolipoprotein and cognitive decline after different whole-brain radiotherapy techniques for breast cancer with brain metastases
Author(s):
WANG Cong; ZHANG Zhilin; LI Jinqiu; SONG Xiao; XI Qiang; MA Huan; LI Ruibiao; TIAN Long
Department of Radiotherapy,the First Affiliated Hospital of Hebei North University,Hebei Zhangjiakou 075000,China.
Keywords:
breast cancer with brain metastases; volume modulated radiotherapy; cognitive decline; apolipoprotein J; apolipoprotein A1
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.19.011
Abstract:
Objective:To investigate the correlation between serum apolipoprotein E(ApoE),ApoJ,ApoA1 and cognitive decline in different radiotherapy techniques on whole-brain radiotherapy(WBRT) for breast cancer with brain metastases.Methods:42 patients with brain metastases from breast cancer were enrolled from the department of radiotherapy,the our hospital from January 2021 to January 2023,which were divided into intensity modulated radiotherapy(IMRT) group and volume modulated radiotherapy(VMAT) group.Serum ApoE,ApoJ,ApoA1 were examined by enzyme-linked immunosorbent assay(ELISA),and cognitive function in patients were evaluated by mini-mental state examination(MMSE).Differential statistical methods were used to analyze the difference of clinical characteristics and serum markers between two groups in pre-and-post treatment,1 month-post-treatment,3 month-post-treatment.Results:At 3 months after treatment,compared with IMRT group,MMSE was higher in VMAT group (P＜0.05),meanwhile,serum ApoE,ApoJ,ApoA1 were significantly decreased in VMAT group (all P＜0.05).There were 19 cases (90.50%) in VMAT group and 13 cases (40.60%) in IMRT group of cognitive dysfunctions,respectively,with statistical significance (P=0.030).The level of ApoE,ApoJ and ApoA1 in patients with cognitive impairment were obviously lower than those in patients with normal cognitive function (all P＜0.05).ROC analysis showed that the area under curve (AUC) of ApoE,ApoJ and ApoA1 were 0.830,0.795 and 0.836,respectively,with difference in statistics (all P＜0.05).Cox multivariate regression analysis showed that the increase of ApoA1 and ApoJ was a protective factor for cognitive-dysfunction-free survival (CDFS) (HR=0.02 and 0.04),the number of metastases was a risk for cognitive decline (HR=7.43).Survival analysis showed that the patients with ApoJ>132.6 pg/mL and ApoA1>150.9 pg/mL had remarkably higher in cognitive decline than those in patients with ApoJ≤132.6 pg/mL and ApoA1≤150.9 pg/mL,respectively (all P＜0.05).Conclusion:Compared with IMRT,VMAT technology has certain advantage in protection patients with cognitive function after WBRT.The decline of cognitive function maybe related to the decrease of serum ApoJ,ApoA1 and the number of metastatic tumors.

References:

［1］LU Q,WANG N,JIANG K,et al.Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population［J］.ESMO Open,2024,9(3):102389.
［2］KIM JS,KIM K,JUNG W,et al.Comparison of initial and sequential salvage brain-directed treatment in patients with 1-4 vs 5-10 brain metastases from breast cancer(KROG 16-12)［J］.Breast Cancer Res Treat,2023,200(1):37-45.
［3］CHERNG HR,SUN K,BENTZEN S,et al.Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect:Asecondary analysis of NRG CC001［J］.Neuro Oncol,2023,12 suppl2(25):1-30.
［4］VANGRINSVENG EE,CIALDELLA F,VERHOEFF J,et al.Different profiles of neurocognitive functioning in patients with brain metastases prior to brain radiotherapy［J］.Psychooncology,2023,32(11):1752-1761.
［5］SRIVASTAVA T,CHIRIKOVA E,BIRK S,et al.Exposure to ionizing radiation and risk of dementia:asystematic review and meta-analysis［J］.Radiat Res,2023,199(5):490-505.
［6］REAS ET,TRIEBSWETTER C,BANKS SJ,et al.Effect of APOE2 and APOE4 on brain microstructure in older adults:modification by age,sex,and cognitive status［J］.Alzheimers Res Ther,2024,16(1):7.
［7］AMPONSAH AE,FENG B,GUO R,et al.Fragmentation of brain apolipoprotein E(ApoE) and its relevance in Alzheimer's disease［J］.Rev Neurosci,2020,31(6):589-603.
［8］MU T,WEI J,SUN J,et al.Association of apolipoprotein E epsilon 4 and cognitive impairment in adults living with human immunodeficiency virus:a meta-analysis［J］.Chin Med J(Engl),2022,135(22):2677-2686.
［9］YOKOYAMA K,KUROSAKI H,OYOSHI H,et al.Plan quality comparison between hippocampus-sparing whole-brain radiotherapy treated with halcyon and tomotherapy intensity-modulated radiotherapy［J］.Technol Cancer Res Treat,2022, 21:15330338221108529.
［10］MASSERA RT,TOMAL A,THOMSON RM.Multiscale monte carlo simulations for dosimetry in x-ray breast imaging:Part Ⅱ-microscopic scales［J］.MED PHYS,2024,51(2):1117-1126.
［11］WU TS,WU PH,LIN HF,et al.Cerebral white matter burden is linked to cognitive function in patients undergoing hemodialysis［J］.Ann Med,2024,56(1):2310142.
［12］QING D,ZHAO B,ZHOU YC,et al.Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer:A single-institution study［J］.Cancer Med,2020,9(1):238-246.
［13］CHIANG PY,HUNG CH,CHANG CC,et al.Hippocampal-sparing whole-brain radiotherapy under coplanar or noncoplanar VMAT［J］.Med Dosim,2023,48(3):134-139.
［14］YANG B,LIANG Y,HE S,et al.Dosimetric comparison of coplanar and noncoplanar volumetric modulated arc therapy for hippocampal-sparing whole-brain radiation therapy［J］.Med Dosim,2023,1(4):1-20.
［15］WEFEL JS,DESHMUKH S,BROWN PD,et al.Impact of apolipoprotein E(APOE) genotype on neurocognitive function(NCF) in patients with brain metastasis(BM):an analysis of NRG oncology's RTOG 0614［J］.Int J Radiat Oncol Biol Phys,2023,5(117):1-25.
［16］HUNTOON K,ANDERSON SK,BALLMAN KV,et al.Association of circulating markers with cognitive decline after radiation therapy for brain metastasis［J］.Neuro Oncol,2023,25(6):1123-1131.
［17］LEE H,AYLWARD AJ,PEARSE RV,et al.Cell-type-specific regulation of APOE and GLU levels in human neurons by the Alzheimer's disease risk gene SORL1［J］.Cell Rep,2023,42(8):112994.
［18］WANG H,MA LZ,SHENG ZH,et al.Association between cerebrospinal fluid clusterin and biomarkers of Alzheimer's disease pathology in mild cognitive impairment:a longitudinal cohort study［J］.Front Aging Neurosci,2023,15:1256389.
［19］ANUSHEE L,AVULA SN,JOSEPH KN,et al.The role of high-density lipoprotein in lowering risk of dementia in the elderly:a review［J］.Cureus,2022,14(4):e24374.
［20］CARON NS,ALY AE,FINDIAY BLACK,et al.Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-1 nanodisks for huntington disease［J］.J Control Release,2024,367:27-44.
［21］NIU X,WANG Y,ZHANG X,et al.Quantitative electroencephalography(qEEG),apolipoprotein A-I(APOA-I),and apolipoprotein epsilon 4(APOE ε4) alleles for the diagnosis of mild cognitive impairment and Alzheimer's disease［J］.Neurol Sci,2024,45(2):547-556.
［22］ROMAGNOLI T,ORTOLANI B,SANZ JM,et al.Serum Apo J as a potential marker of conversion from mild cognitive impairment to dementia［J］.J Neurol Sci,2021,427:117537.
［23］ANDRADE V,M RODRIGUES EY,DIAS N,et al.Neuroprotective profile of triazole grandisin analogue against amyloid-beta oligomer-induced cognitive impairment［J］.ACS Chem Neurosci,2023,14(24):4298-4310.
［24］KO YA,BILLHEIMER JT,LYSSENKO NN,et al.ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease［J］.Alzheimers Res Ther,2022,14(1):194.

Memo

Memo:
河北省医学科学研究课题计划项目（编号：20220595）
Last Update: 2024-08-30